CAR-T Cells for HIV Infection
NCT04648046 is a phase 1/2 interventional trial sponsored by Steven Deeks. As of 21 Nov 2026, it is active and no longer recruiting. It studies Cyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose in HIV Infections. The registry lists an enrollment of 11 participants at 2 sites in 1 country. The registry lists a start date of 1 Mar 2021 and a primary completion date of 31 Dec 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04648046 |
| Status | Active not recruiting |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Steven Deeks |
| Enrollment | 11 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | HIV Infections |
| Drugs | Cyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose |
| Start | 1 Mar 2021 |
| Primary completion | 31 Dec 2028 |
| Study completion | 31 Dec 2029 |
| Last update posted | 14 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, Davis
Sacramento
- Zuckerberg San Francisco General
San Francisco
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04648046
Each answer restates registry values shown on this page.
What is NCT04648046?
NCT04648046 is a phase 1/2 interventional trial sponsored by Steven Deeks. It studies Cyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose in HIV Infections.
Is NCT04648046 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT04648046?
The registry names Steven Deeks, MD (principal investigator, University of California, San Francisco) as the overall official.
Where does NCT04648046 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04648046 study?
The registered drug and biological interventions are Cyclophosphamide, LVgp120duoCAR-T cells, high dose and LVgp120duoCAR-T cells, low dose.
When is NCT04648046 expected to complete?
The registry lists a primary completion date of 31 Dec 2028 and a study completion date of 31 Dec 2029. The sponsor last updated the record on 14 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.